Evidence mapPaperPMID 39790707Full record

ReviewMedicine international

Exploring oncology treatment strategies with tyrosine kinase inhibitors through advanced 3D models (Review).

Giorgia Isinelli, Sharon Failla, Roberto Plebani, Alessandro Prete

Abstract readReview
In one paragraph

Review in Medicine international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Giorgia IsinelliDepartment of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA.
Sharon FaillaDepartment of Biomedical and Biotechnological Sciences, University of Catania, I-95123 Catania, Italy.
Roberto PlebaniDepartment of Medical, Oral and Biotechnological Sciences, 'G. D'Annunzio' University, I-66100 Chieti-Pescara, Italy.
Alessandro PreteDepartment of Clinical and Experimental Medicine, Endocrine Unit 2, University of Pisa, I-56122 Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The limitations of two-dimensional (2D) models in cancer research have hindered progress in fully understanding the complexities of drug resistance and therapeutic failures. However, three-dimensional (3D) models provide a more accurate representation of

Indexed as

3D modelsoncologytumor microenvironmenttyrosine kinase inhibitors

Identifiers

PMID39790707
PMCPMC11707505

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.